Biodesix, Inc. (NASDAQ:BDSX) Short Interest Update

Biodesix, Inc. (NASDAQ:BDSX) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totaling 483,591 shares, an increase of 499.1% from the December 31st total of 80,722 shares. Based on an average trading volume of 7,865,756 shares, the days-to-cover ratio is currently 0.1 days. Currently, 8.7% of the shares of the stock are sold short. Currently, 8.7% of the shares of the stock are sold short. Based on an average trading volume of 7,865,756 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Biodesix has an average rating of “Moderate Buy” and an average price target of $32.50.

Biodesix Trading Down 6.8%

NASDAQ:BDSX opened at $10.33 on Thursday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The firm has a fifty day simple moving average of $7.82 and a 200-day simple moving average of $7.74. The company has a market capitalization of $82.23 million, a P/E ratio of -1.86 and a beta of 0.60. Biodesix has a 12 month low of $3.44 and a 12 month high of $21.60.

Biodesix (NASDAQ:BDSX) last released its earnings results on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. The firm had revenue of $21.77 million during the quarter, compared to the consensus estimate of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. On average, equities research analysts anticipate that Biodesix will post -0.35 earnings per share for the current year.

Key Biodesix News

Here are the key news stories impacting Biodesix this week:

• Positive Sentiment: Director Jack W. Schuler has been buying shares in multiple transactions (totaling roughly 180k+ shares across late Jan, at average prices ~$10.96–$11.81), signaling insider confidence and providing a near?term demand tailwind. Jack Schuler Acquires 20,000 Shares of Biodesix
• Positive Sentiment: Hedge funds/institutions have added positions (e.g., Aberdeen Group’s new ~$1.78M stake; new positions by Millennium Management and Oracle Investment Management), which can provide steadier bid support. Institutional holdings summary
• Positive Sentiment: Analyst coverage is mixed but skewed bullish: four Buy, one Hold, one Sell; consensus is a “Moderate Buy” with an average target near $32.50, giving upside versus current levels if execution and growth continue.
• Neutral Sentiment: Fundamentals and valuation provide context but not a clear near?term driver: recent quarter beat EPS and revenue estimates but the company remains unprofitable (negative margins, negative ROE); liquidity ratios are modestly healthy. These items support a watchful stance rather than an immediate directional verdict.
• Negative Sentiment: Short interest reportedly jumped to ~483,591 shares as of Jan 15 (up ~499% from Dec 31), representing ~8.7% of shares sold short. Increased short positioning can weigh on the stock and indicate bearish sentiment or hedging activity; it also raises headline risk.
• Negative Sentiment: Conflicting/erroneous short?interest reports (some feeds showing 0 shares or NaN changes) create uncertainty about the true short position and may amplify intraday volatility as traders reconcile data discrepancies.

Insider Transactions at Biodesix

In other Biodesix news, Director Jack W. Schuler bought 20,000 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was purchased at an average cost of $11.80 per share, with a total value of $236,000.00. Following the completion of the acquisition, the director owned 1,563,210 shares in the company, valued at $18,445,878. This trade represents a 1.30% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders purchased 182,465 shares of company stock valued at $2,084,616 and sold 2,247 shares valued at $18,154. 30.10% of the stock is currently owned by insiders.

Institutional Trading of Biodesix

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd boosted its stake in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after acquiring an additional 102,494 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Biodesix in the 3rd quarter valued at approximately $113,000. Oracle Investment Management Inc. purchased a new position in shares of Biodesix during the 3rd quarter worth $113,000. Finally, Aberdeen Group plc purchased a new stake in shares of Biodesix in the 4th quarter valued at approximately $1,784,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.